📊 ICUI Key Takeaways
Is Icu Medical Inc./de (ICUI) a Good Investment?
ICU Medical's 2787% revenue spike indicates a major acquisition, but the company is severely struggling with profitability and debt service. With 0.5x interest coverage, operating margins of 1.9%, and net profitability near zero on $2.2B revenue, the integration appears challenged and operationally stressed despite positive free cash flow.
ICU Medical has scaled to $2.23B in revenue with solid gross margins and healthy liquidity, producing positive free cash flow. However, operating and net profitability are minimal and interest coverage is below 1x, signaling earnings pressure from leverage and integration costs. Sustained margin expansion and improved coverage are needed before a more constructive view.
Why Buy Icu Medical Inc./de Stock? ICUI Key Strengths
- Positive operating and free cash flow generation ($179.8M and $91.8M respectively)
- Strong liquidity position with 2.39x current ratio and $308M cash reserves
- Reasonable debt/equity ratio of 0.60x indicating moderate leverage
- Healthy liquidity (current ratio 2.39x; quick 1.15x)
- Positive free cash flow with cash balance support
- Solid gross margin (36.8%) and diversified device/consumable mix
ICUI Stock Risks: Icu Medical Inc./de Investment Risks
- Critical: Interest coverage of 0.5x means operating income cannot service debt obligations
- Acquisition integration failure: 2787% revenue growth paired with 0.0% net margin and 1.9% operating margin suggests severe operational distress
- Minimal profitability: $732K net income on $2.2B revenue indicates structural profitability issues, not temporary margin compression
- Very low operating and net margins (~1.9% and ~0%)
- Weak interest coverage (0.5x) heightens refinancing/earnings risk
- Integration/execution risk behind rapid revenue growth
Key Metrics to Watch
- Interest coverage ratio - must improve above 1.0x for financial stability
- Operating margin expansion from 1.9% baseline
- Acquisition synergy realization and integration timeline
- Operating margin and FCF margin trend
- Interest coverage and net leverage
Icu Medical Inc./de (ICUI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 4.1% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.39x current ratio provides a solid financial cushion.
ICUI Profit Margin, ROE & Profitability Analysis
ICUI vs Healthcare Sector: How Icu Medical Inc./de Compares
How Icu Medical Inc./de compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Icu Medical Inc./de Stock Overvalued? ICUI Valuation Analysis 2026
Based on fundamental analysis, Icu Medical Inc./de shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Icu Medical Inc./de Balance Sheet: ICUI Debt, Cash & Liquidity
ICUI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Icu Medical Inc./de's revenue has grown significantly by 81% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.23 indicates the company is currently unprofitable.
ICUI Revenue Growth, EPS Growth & YoY Performance
ICUI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $537.0M | -$3.4M | $-0.14 |
| Q2 2025 | $548.9M | -$15.5M | $0.80 |
| Q1 2025 | $566.7M | -$15.5M | $-0.63 |
| Q3 2024 | $553.3M | $7.2M | $0.30 |
| Q2 2024 | $549.3M | -$9.8M | $-0.41 |
| Q1 2024 | $566.7M | -$9.8M | $-0.41 |
| Q3 2023 | $553.3M | $7.2M | $0.30 |
| Q2 2023 | $549.3M | -$7.5M | $-0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Icu Medical Inc./de Dividends, Buybacks & Capital Allocation
ICUI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Icu Medical Inc./de (CIK: 0000883984)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ICUI
What is the AI rating for ICUI?
Icu Medical Inc./de (ICUI) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ICUI's key strengths?
Claude: Positive operating and free cash flow generation ($179.8M and $91.8M respectively). Strong liquidity position with 2.39x current ratio and $308M cash reserves. ChatGPT: Healthy liquidity (current ratio 2.39x; quick 1.15x). Positive free cash flow with cash balance support.
What are the risks of investing in ICUI?
Claude: Critical: Interest coverage of 0.5x means operating income cannot service debt obligations. Acquisition integration failure: 2787% revenue growth paired with 0.0% net margin and 1.9% operating margin suggests severe operational distress. ChatGPT: Very low operating and net margins (~1.9% and ~0%). Weak interest coverage (0.5x) heightens refinancing/earnings risk.
What is ICUI's revenue and growth?
Icu Medical Inc./de reported revenue of $2.2B.
Does ICUI pay dividends?
Icu Medical Inc./de does not currently pay dividends.
Where can I find ICUI SEC filings?
Official SEC filings for Icu Medical Inc./de (CIK: 0000883984) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ICUI's EPS?
Icu Medical Inc./de has a diluted EPS of $0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ICUI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Icu Medical Inc./de has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ICUI stock overvalued or undervalued?
Valuation metrics for ICUI: ROE of 0.0% (sector avg: 15%), net margin of 0.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ICUI stock in 2026?
Our dual AI analysis gives Icu Medical Inc./de a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ICUI's free cash flow?
Icu Medical Inc./de's operating cash flow is $179.8M, with capital expenditures of $88.0M. FCF margin is 4.1%.
How does ICUI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 0.0% (avg: 12%), ROE 0.0% (avg: 15%), current ratio 2.39 (avg: 2).